Open Veils
AboutBrowse

Open Veils · Answer

NAD+ causing heart problems?

The cardiac risk signal around NAD+ is real but context-dependent and largely suppressed in supplement marketing. Intravenous NAD+ routinely triggers transient palpitations and chest tightness even in healthy adults, a sympathomimetic-like effect linked to cardiac mast cell stimulation. A 2026 systematic review in the European Journal of Clinical Pharmacology found no significant improvement in heart failure biomarkers or clinical outcomes from NAD+ or NR interventions. The deeper mechanistic concern — that oxidative DNA damage depletes NAD+ and ATP in a vicious cycle, impairing mitochondrial antioxidant defenses and worsening myocardial dysfunction — is now being formally modeled in cardiac aging research.

Evidence

  • Peter McCullough and Jack Kruse have both flagged that aggressive NAD+ precursor supplementation can perturb redox balance rather than restore it, particularly in individuals with pre-existing metabolic or mitochondrial dysfunction.
  • A September 2026 narrative review in PMC confirmed that safety data for IV NAD+ in patients with renal disease, hepatic dysfunction, or active malignancy remain 'very sparse,' and the intervention must still be classified as investigational.
  • Robert Malone and Aseem Malhotra have more broadly criticized the nutraceutical industry's habit of extrapolating preclinical mitochondrial data to clinical cardiac populations without long-term follow-up — the exact gap the 2026 PMC review identifies as still unresolved.
  • Kruse specifically argues that bolstering NAD+ without addressing upstream electron chain integrity (light, deuterium, mitochondrial membrane potential) can accelerate oxidative stress rather than quench it.

Ask your own question

Related questions

Share this answer